43 results about "Coagulase test" patented technology

A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.

Proteins and polypeptides from coagulase-negative staphylococcal bacteria such as S. epidermidis, including proteins designated SdrF, SdrG and SdrH, and their effective fragments such as their respective A domains, are provided which are useful in the prevention and treatment of infection caused by coagulase-negative staphylococcal bacteria such as S. epidermidis. The SdrF, SdrG and SdrH proteins are cell-wall associated proteins that specifically bind host proteins and which each have a highly conserved motif of which the consensus sequence is TYTFTDYVD (SEQ ID NO: 16). The proteins and polypetides may be useful in generating antibodies for the diagnosis and treatment of coagulase-negative staphylococcal infections.

The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compositions, including pharmaceutical compositions of immunoglobulin and isolated antigen.

The invention provides a five-item quality control product of an AV / BV combined test kit and a preparation method thereof, belonging to quality control products for controlling the quality of kits used during female gynecological clinical detection. The quality control product comprises a vaginal discharge five-item positive quality control product and a vaginal discharge five-item negative quality control product, and the two types of quality control products are stored in the states of dry powder. The quality control product is used to carry out quality detection of a vaginitis test kit and can carry out quality control on five biochemical indexes including hydrogen peroxide, neuraminidase, leucocyte esterase, beta-glucuronidase and coagulase. By means of taking biological enzymes as active ingredients of the quality control product and preparing a dry powder quality control product by adopting a freezing-drying technology, the deactivation of a liquid quality control product in transportation and storage processes is avoided. The quality control product does not contain any human vaginal discharge, and does not cause infection to the environment and operators.

Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.

A dry mixture, a liquid menstrum, and a method, are described for use in detecting the presence or absence of Methicillin Resistant Staphylococcus aureus (“MRSA”) in a first generation biological or environmental specimen sample. First generation specimen samples that can be analyzed include nasal swabs, lesion swabs, skin swabs, throat swabs, food swabs, tanning salon swabs, gym swabs, restaurant swabs, hotel swabs, and the like. The menstrum and method include an anti-ribosomal antibiotic component that will selectively prevent Methicillin Susceptible Staphylococcus aureus (“MSSA”) from growing in the menstrum, while allowing MRSA to grow in the menstrum. The menstrum also includes components which will stimulate growth of MRSA, plus coagulase reacting factors which will cause the menstrum to clot in the event that MRSA is present in the sample. The menstrum also includes components which will produce a detectable signal in the clot, which signal indicates the presence of MRSA in the sample.

This invention relates to the use of genetic probes for detection of the presence of the SCCmec cassette in Staphylococcus aureus. In one aspect, the invention allows specific detection and identification of methicillin-resistant S. aureus (MRSA) in a clinical sample without interference from the presence of other non-S. aureus methicillin-resistant staphylococci. In another aspect, the invention allows specific detection and identification of methicillin-resistant coagulase negative staphylococci (MRCNS) originating from a clinical sample without interference from the presence of methicillin-resistant S. aureus.

The invention provides a method for rapidly detecting staphylococcus aureus in diet. The method comprises the following steps: 1) culture enrichment: weighing a sample to sodium chloride broth, and carrying out anaerobic culture after homogenization; 2) separation: carrying out streak inoculation on a culture after culture enrichment to a staphylococcus aureus selective flat plate, and carrying out anaerobic culture; 3) preliminary identification: preliminarily determining a staphylococcus aureus bacterial colony according to morphology; and 4) confirmation identification: inoculating suspicious bacteria on the staphylococcus aureus selective flat plate on a blood plate, culturing, observing whether the suspicious bacteria are dissolved in blood, selecting bacterial colonies which are dissolved in blood and carrying out biochemical identification by using a VITEK 2 COMPACT full-automatic microorganism analyzing system to obtain the result. Compared with the prior art, the method has the advantages that by the characteristics that the staphylococcus aureus is aerobic and anaerobic bacteria, and the metabolites of the staphylococcus aureus can produce plasma-coagulase, the suspiciousbacteria which are not dissolved in blood do not need to be identified, the staphylococcus aureus detecting time is shortened, and the detecting difficulty is reduced.

The present invention relates to compositions of staphylococcal deacetylated poly-N-acetylglucosamine (dPNAG). Deacetylated poly-N-acetylglucosamine can be isolated from natural sources or synthesized de novo. The present invention also relates to the use of deacetylated poly-N-acetylglucosamine as a vaccine to induce resistance to Staphylococcus aureus, Staphylococcus epidermidis, other related coagulase-negative or coagulase-positive staphylococci, and other carrier intracellular Active immunity to infection by organisms attached to loci. The present invention also provides a method for using the antibody targeting deacetylated poly-N-acetylglucosamine, especially a method for inducing passive immunity against similar infections.

The invention discloses a method for quantitatively detecting staphylococcus aureus in food. The method comprises four steps of preparation, sample preparation, culture and counting. After a sample isprepared, each dilution sample sucks 1mL of sample homogenate into a culture dish, then adding 15-20mL of a Baird-Parker culture medium solution added with potassium tellurite egg yolk enrichment broth into each culture dish, performing uniform mixing, then performing culturing, counting suspicious colonies after culturing, and carrying out confirmation and identification on the suspicious colonies by virtue of a plasma coagulase test. Different from existing coating methods, the method provided by the invention can be used for rapidly, simply, conveniently and accurately determining staphylococcus aureus in food.

This invention relates to the use of genetic probes for detection of the presence of the SCCmec cassette in Staphylococcus aureus. In one aspect, the invention allows specific detection and identification of methicillin-resistant S. aureus (MRSA) in a clinical sample without interference from the presence of other non-S. aureus methicillin-resistant staphylococci. In another aspect, the invention allows specific detection and identification of methicillin-resistant coagulase negative staphylococci (MRCNS) originating from a clinical sample without interference from the presence of methicillin-resistant S. aureus.

The invention discloses a primer, kit and method for detecting staphylococcus aureus through a PCR (Polymerase Chain Reaction)-pyrophosphate method. In the invention, a PCR primer and a sequencing primer are designed via PyroMark Assay Design software according to a conserved region in a staphylococcus aureus plasma-coagulase DNA base sequence; and then a method for detecting staphylococcus aureus from the level of the DNA base sequence is established through a PCR-pyrophosphate sequencing method. In the invention, PCR augmentation is firstly carried out on a target segment under the condition of ensuring the specificity of the augmented segment; then a single-chain template is prepared from the augmented product; and then pyrophosphate sequencing is carried out under the guide of the sequencing primer. The base sequences obtained behind the plasma-coagulase DNA sequencing primer are discovered to have good specificity through repeated comparison by using a BLAST function of an NCBI (National Center of Biotechnology Information) website; and the staphylococcus aureus can be identified when 29 DNA base sequences behind the sequencing primer are CAACCGACGACACCGAACCCTATTTTAGA.

The invention discloses a drug for repairing tunica mucosa bronchiorum. The drug is prepared by extracting lecithin, amino acid, pseudo-ginseng, saffron crocus and free-ion coagulase in an extraction tank so as to obtain medicinal liquid, filtering, evaporating and concentrating the medicinal liquid, and drying in vacuum to obtain dry medicinal powder. The drug disclosed by the invention is capable of effectively repairing injured tunica mucosa bronchiorum and promoting healing of bronchus.